Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial.

Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Ann Am Thorac Soc. 2021 07; 18(7):1147-1157.

View in: PubMed

subject areas

Administration, Inhalation
Adult
Amikacin
Anti-Bacterial Agents
Humans
Liposomes
Lung Diseases
Mycobacterium avium Complex
Mycobacterium avium-intracellulare Infection
Treatment Outcome

authors with profiles

Patrick A. Flume